Kronox Lab Sciences Publishes Q3 FY26 Unaudited Financial Results
Kronox Lab Sciences Limited announced its unaudited financial results for the quarter ended December 31, 2025. Consolidated total income was ₹10.58 crore with a net profit after tax of ₹6.10 crore. Standalone total income was ₹10.58 crore with a net profit after tax of ₹5.22 crore. Nine-month consolidated income was ₹37.18 crore (net profit ₹46.19 crore), and standalone income was ₹46.04 crore (net profit ₹68.15 crore).
This is a standard disclosure of unaudited financial results, which is a routine event for listed companies. The information provided is factual and does not contain any significant new strategic information or performance indicators that would heavily influence the stock.
The announcement is a routine publication of financial results, providing factual data without any commentary that would suggest a positive or negative market reaction.
Kronox Lab Sciences Limited has announced the publication of its Unaudited Financial Results for the quarter ended December 31, 2025. The results were published in the Indian Express (English) and Financial Express (Gujarati) newspapers on February 16, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
The company provided extracts of the financial statements, including both consolidated and standalone figures. For the quarter ended December 31, 2025, the consolidated total income was ₹10.58 crore, with a net profit after tax of ₹6.10 crore. The standalone total income for the same period was also ₹10.58 crore, with a net profit after tax of ₹5.22 crore.
For the nine months ended December 31, 2025, the consolidated total income stood at ₹37.18 crore, and the net profit after tax was ₹46.19 crore. The standalone nine-month income was ₹46.04 crore, with a net profit after tax of ₹68.15 crore. The company's share capital remains ₹19.80 crore.
What to do with a filing like this
Kronox Lab Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kronox Lab Sciences Limited. Read the original for the full detail.